What are the pharmacokinetic properties of rituximab, including its route of administration, distribution volumes, metabolism, elimination half‑life, and dosing considerations?

Pharmacokinetics of Rituximab

Route of Administration and Formulations

Rituximab is administered intravenously, with a subcutaneous formulation also available that achieves noninferior exposure to IV dosing. 1

• The standard IV dosing schedule is 375 mg/m² weekly for 4 doses across most indications 2
• Alternative dosing includes two 1,000 mg infusions separated by 2 weeks, which shows equivalent efficacy 3
• Subcutaneous formulation demonstrates similar pharmacokinetic disposition and elimination to IV administration 1

Distribution and Volume of Distribution

The volume of distribution varies significantly by underlying disease, ranging from 2.28 to 3.91 L in different patient populations. 2

• In rheumatoid arthritis patients, the volume of distribution is 3.1 L 2
• In GPA/MPA patients, the median volume ranges from 2.28 L (pediatric) to 3.12 L (adult) 2
• Central volume of distribution is 1.7-fold higher in DLBCL compared to RA, FL, and CLL 4
• Body surface area (BSA) is the predominant factor influencing volume of distribution 2, 1

Elimination Half-Life

The terminal elimination half-life of rituximab ranges from 18 to 32 days depending on the underlying disease. 2

• In NHL patients: median 22 days (range 6.1–52 days) 2
• In CLL patients: median 32 days (range 14–62 days) 2
• In RA patients: mean 18.0 days (range 5.17–77.5 days) 2
• In GPA/MPA patients: median 25 days (range 11–52 days) in adults and 22 days (range 11–42 days) in pediatrics 2
• In pemphigus vulgaris: median 21.1 days after first cycle, increasing to 26.2 days after second cycle 2

Clearance and Metabolism

Rituximab clearance is influenced by target-mediated drug disposition, with higher clearance in diseases with greater tumor burden or CD20-positive cell counts. 4

• In RA patients, estimated clearance is 0.335 L/day 2
• In GPA/MPA patients, median clearance ranges from 0.222 L/day (pediatric) to 0.279 L/day (adult) 2
• Patients with higher CD19-positive cell counts or larger tumor lesions have higher clearance 2
• First-order elimination rate constants are 1.8-fold higher in RA, DLBCL, and FL compared to CLL 4
• Male patients and those with higher BSA demonstrate increased clearance 2

Serum Detectability and Steady-State Concentrations

Rituximab remains detectable in serum for 3–6 months after treatment completion, with steady-state achieved after 6–8 weekly infusions. 5

• After 4 weekly infusions, rituximab concentration reaches approximately 2.5 μg/mL, which is ~85% of steady-state 5
• Mean peak concentrations (Cmax) after two 1,000 mg doses are 318–381 μg/mL 2
• Minimum steady-state serum concentration (Ctrough) is the most appropriate exposure bridging measure 1

Factors Affecting Pharmacokinetics

Age and gender do not significantly affect rituximab pharmacokinetics in NHL and RA patients, but disease-specific factors substantially influence drug exposure. 2

• Baseline latent antigen level is 54-fold higher in CLL, 20-fold higher in DLBCL, and 29-fold higher in FL compared to RA and AAV 4
• In lymphomas, baseline total metabolic tumor volume increases latent antigen levels (p = 6.10⁻⁷) 4
• In CLL, target-mediated elimination increases with baseline CD20 count on circulating B cells (p = 0.0081) 4
• Positive anti-rituximab antibody levels increase clearance, though dose adjustment is not necessary 2

Dosing Considerations by Indication

Standard dosing is 375 mg/m² weekly for 4 weeks, but alternative regimens may be appropriate based on disease and treatment goals. 6, 7, 8

• GPA/MPA induction: 375 mg/m² weekly for 4 weeks 7, 8
• GPA/MPA maintenance: 500 mg every 6 months 8
• ITP: 375 mg/m² weekly for 4 weeks, with 79% durable remission when combined with high-dose dexamethasone in newly diagnosed adult females 6, 8
• Inflammatory myositis: Either two 1,000 mg doses 2 weeks apart or 375 mg/m² weekly for 4 weeks 3, 8
• Chronic GVHD: 375 mg/m² weekly for 4–8 infusions (or 50 mg/m² weekly for 4 weeks) 9, 8
• Follicular lymphoma maintenance: 375 mg/m² every 8 weeks for 12 doses or every 12 weeks for 2 years 10, 8

Immunologic Effects

Rituximab induces near-complete B-cell depletion within 2 weeks, with variable recovery patterns and potential for prolonged hypogammaglobulinemia. 2

• Majority of patients achieve CD19 counts below 20 cells/μL within 2 weeks 2
• B-cell depletion persists for at least 6 months in most patients 2
• Approximately 4% of RA patients experience prolonged B-cell depletion lasting >3 years 2
• IgG levels decline at a mean rate of 0.35 g/L/year (95% CI 0.25–0.44; p < 0.001) 11
• Hypogammaglobulinemia (<6.7 g/L) occurs in 7.5% of patients 11
• In RA patients, 23.3% develop decreased IgM, 5.5% decreased IgG, and 0.5% decreased IgA below normal limits during repeated treatment 2